Lacktman Discusses CMS’ Physician-Texting Position Amid Reports of Banning mHealth Messaging
29 December 2017
Partner Nate Lacktman was quoted in an mHealthIntelligence article, “CMS Clarifies Texting Rules Amid Rumors of mHealth Message Ban,” about the Centers for Medicare & Medicaid Services’ position on physician texting following reports that the agency was planning to ban the mHealth messaging platform. CMS Survey and Certification Group Director David Wright confirmed that texting patient information among patient care providers is permitted if sent via a secure messaging platform and texting patient orders is forbidden, regardless of the platform, and must only be submitted via a certified provider order entry.
mHealthIntelligence referenced Lacktman’s Dec. 29 LinkedIn post, in which he reiterated that the CMS hasn’t changed its position on physician texting and that it aligns with the Joint Commission’s position, which was last updated in 2016.
mHealthIntelligence referenced Lacktman’s Dec. 29 LinkedIn post, in which he reiterated that the CMS hasn’t changed its position on physician texting and that it aligns with the Joint Commission’s position, which was last updated in 2016.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”